Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases
With TX01 and Batten-1, THX Pharma is entering a new strategic phase focused on regulatory approval, earl...
Theranexus and Beyond Batten Disease Foundation Announce Strong Positive Real-World Data Supporting Batten-1 Efficacy for the Treatment of Batten Disease
Lyon, France – Austin, Texas, United States – Mai 13, 2025 – 6.00 pm CET –Theranexus, a biopharmaceutica...
Family Research Calls – May 13 & 15
Dear BBDF Family Partners, Please join us on our next two family research calls. You will need to regi...
Batten Disease Global Research Initiative Announces Inaugural Grant Recipients
March 18, 2025 Batten Disease Global Research Initiative Announces Inaugural Grant Recipients The B...
Batten-1 May Preserve Vision with Juvenile Batten Disease
Findings in Phase 1/2 clinical trial, access program also support miglustat's safety. by Margarida Maia,...
Update on the Theranexus’ Batten-1 project in CLN3 Batten’s disease
Lyon, France – Austin, Texas, United States – November 19, 2024 – 6 PM CET – Theranexus, a biopharmaceuti...
NORD Batten Disease Patient Assistance Program Reminder
Reminder that NORD's Batten Disease Premium & Copay Patient Assistance Program is open and accepting...
We Need Your Help Re: Off-Label Miglustat Use
As we have previously reported, the Phase III trial for Batten-1 is experiencing some unanticipated delay...
Batten Disease Research Priorities (Phase 2) – YOUR HELP REQUESTED
Dear Batten community, Phase 2 of the Batten disease research priority-setting process is underway and...
Theranexus and BBDF Confirm Positive 18-Month Results for Batten-1 in Phase I/II Trial Based on Neuronal Death Biomarker Values
Lyon, France – Austin, Texas, United States – 6 June 2024 – 7:30am CT – Theranexus, a biopharmaceutical c...